TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
EMPLOYEES
Incyte Biosciences Nordic AB
Closing information (x1000 NOK)
| Closing information | 2023/12 | 2022/12 | 2021/12 |
| Turnover |
39,144
|
30,981
|
28,102 |
| Financial expenses |
9
|
43
|
32 |
| Earnings before taxes |
1,762
|
1,321
|
1,481 |
| EBITDA |
1,733
|
1,461
|
1,687 |
| Total assets |
13,110
|
15,870
|
15,561 |
| Current assets |
10,982
|
15,762
|
15,348 |
| Current liabilities |
7,914
|
12,028
|
12,408 |
| Equity capital |
5,196
|
3,841
|
3,153 |
| - share capital |
51
|
47
|
49 |
| Employees (average) |
10
|
9
|
7 |
Financial ratios
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Solvency |
39.6%
|
24.2%
|
20.3% |
| Turnover per employee |
3,914
|
3,442
|
4,015 |
| Profit as a percentage of turnover |
4.5%
|
4.3%
|
5.3% |
| Return on assets (ROA) |
13.5%
|
8.6%
|
9.7% |
| Current ratio |
138.8%
|
131.0%
|
123.7% |
| Return on equity (ROE) |
33.9%
|
34.4%
|
47.0% |
| Change turnover |
5,965
|
3,723
|
7,197 |
| Change turnover % |
18%
|
14%
|
34% |
| Chg. No. of employees |
1
|
2
|
1 |
| Chg. No. of employees % |
11%
|
29%
|
17% |
Total value of public sale
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.